The truth about Psilocybin therapy with Magic Mushrooms.
The resurgence of interest in psilocybin therapy is redefining how we approach mental health, with mounting research supporting the use of magic mushrooms in clinical settings. As healthcare professionals and scientists delve deeper into microdosing psychedelics, the therapeutic potential of these natural compounds is becoming harder to ignore. However, the evolving conversation must also account for the vast diversity of psychedelic mushroom species, each with unique biochemical profiles and effects. Despite the promising findings, the legal status of psychedelics continues to pose significant barriers, underscoring the need for informed policy reform and public education.
Important Notice
This article explores substances such as psilocybin (commonly found in magic mushrooms), LSD, and MDMA, focusing on their potential therapeutic use in clinical environments. It is intended for educational purposes only and highlights the growing body of research surrounding psilocybin therapy and its implications in mental healthcare.
Please be aware that the legal status of psychedelics varies significantly around the world. In many jurisdictions, the use, possession, or distribution of these substances remains illegal. Individuals should not consume or engage with these compounds outside of a legally approved research or treatment program. The question “Are mushroom grow kits in UK illegal?” remains relevant for readers exploring cultivation as part of psychedelic mushroom species education.
SporeBuddies.com does not accept liability for decisions made based on this article. Always consult a licensed medical professional before pursuing any form of treatment involving psychedelics. By continuing, you acknowledge that SporeBuddies.com is not responsible for any legal, physical, or psychological consequences tied to the information shared here.

Magic Mushrooms in Holistic Mental Health Treatment
Across history, magic mushrooms have served a central role in traditional healing, spiritual exploration, and ritual. Now, modern science is revisiting these traditions through the lens of psilocybin therapy, uncovering compelling evidence for their use in treating mental illness. The therapeutic benefits of psilocybin mushrooms are gaining traction among clinicians and researchers alike.
Despite these promising developments, the legal status of psychedelics continues to hinder their integration into mainstream healthcare. In many regions, these substances remain under strict prohibition, reflecting a legacy of outdated policy rather than current medical insight.
How Psilocybin Works in the Brain
The active compound in magic mushrooms, known as psilocybin, engages serotonin receptors in the brain—specifically the 5-HT2A receptor—leading to altered states of consciousness. This biochemical mechanism underpins the core of psilocybin therapy, which is gaining popularity as a novel mental health intervention.
Clinical Benefits Backed by Research
Recent scientific studies supporting psilocybin treatment have revealed exciting possibilities for mental health care. These include:
Depression: A pivotal 2020 study in JAMA Psychiatry demonstrated that psilocybin therapy significantly reduces depressive symptoms, especially when traditional treatments fail.
Anxiety: Findings from Johns Hopkins University showed that even a single dose of psilocybin reduced anxiety and depression in terminally ill cancer patients.
PTSD: Preliminary research suggests that controlled psilocybin experiences allow patients to safely revisit and process trauma.
Addiction: Promising data supports psilocybin’s role in reducing substance dependence, such as with alcohol and tobacco.
These results are foundational to the discussion around how microdosing psilocybin works for depression, as well as its broader psychological benefits.
As more clinicians investigate the microdosing psychedelics approach, they often report enhanced neuroplasticity, emotional openness, and resilience. These properties suggest that psilocybin therapy could become a key component of integrative mental health practices.
Why Is Psilocybin Still Illegal?
Historical and Political Influences
The current legal status of psychedelics is heavily influenced by historical events rather than clinical evidence. During the 1960s, the use of magic mushrooms and other hallucinogens became symbolic of countercultural rebellion. This prompted a strong political reaction, culminating in the U.S. Controlled Substances Act of 1970, which categorized psilocybin as a Schedule I drug—denoting it as having no recognized medical use and a high potential for abuse.
This classification had far-reaching consequences, shaping international law through agreements like the 1971 UN Convention on Psychotropic Substances. The legal history of psychedelic mushrooms in the US laid the foundation for decades of restricted access and delayed research, hindering the progress of psilocybin therapy for generations. Magic mushroom laws Europe – INFO – Spore Buddies
Modern-Day Barriers to Acceptance
Today, even as evidence mounts in favor of psilocybin therapy and microdosing psychedelics, the path to widespread adoption remains fraught with challenges:
Regulatory Complexity: Shifting a Schedule I substance to a medically approved category is a lengthy, data-heavy process that slows innovation.
Public Misconceptions: For years, the public has been conditioned to associate psychedelic mushroom species with danger, despite a low incidence of harm when used responsibly.
Pharmaceutical Pushback: Many companies are resistant to embracing natural alternatives to antidepressants using mushrooms, which can’t be easily patented or monetized under conventional business models.
Policy Conservatism: Fear of endorsing recreational use causes some lawmakers to hesitate—even when presented with scientific facts.
These hurdles illustrate the complex dynamic between politics, profit, and science that continues to shape the legal status of psychedelics.
Shifting Legal Landscapes and Future Outlook
In recent years, there’s been a noticeable shift in how lawmakers and the public view psilocybin therapy. A growing number of cities and regions are easing restrictions on magic mushrooms, recognizing both their cultural significance and their emerging therapeutic value.
Denver and Oakland have decriminalized psilocybin use.
Oregon now permits regulated therapeutic applications under medical supervision.
Canada and parts of Europe are supporting clinical trials focused on microdosing psychedelics and the safe administration of full therapeutic doses.
Such progress is promising—but to maintain momentum, sustained public education is crucial. Campaigns that demystify microdosing psychedelics and promote the FDA approval process for psychedelic therapy are pivotal in convincing lawmakers to consider reform.
A Framework for Clinical Microdosing
For microdosing psychedelics to become a legitimate medical treatment, a clear and evidence-based clinical framework is essential. Many healthcare professionals now view psilocybin therapy as a promising tool for transforming psychiatric care—especially in cases where conventional methods fail.
Regulatory Approval and Guidelines
Securing approval from regulatory bodies like the FDA and EMA is a necessary step in formalizing protocols. Dosing guidelines generally recommend 1/10 to 1/20 of a full dose—for example, 0.1 to 0.3 grams of dried psychedelic mushroom species. A common regimen involves taking a microdose once every three days under observation.
Read our guide on How to microdose mushrooms – Spore Buddies
As more studies reveal the comprehensive list of psychedelic mushroom species suitable for therapeutic use, medical standards are evolving to reflect both safety and efficacy.
Training and Patient Monitoring
Healthcare providers must undergo thorough training in psychedelic medicine. Programs should also offer certification in areas such as what to know before using magic mushrooms for therapy, ensuring informed and safe practices.
Patient care includes:
Regular psychological assessments
Access to integration therapy for emotional support
Screening for conditions like psychosis or heart irregularities
It’s essential that both patients and providers remain aware of the legal status of psychedelics in their region and obtain appropriate informed consent.
Microdosing: A Controlled Medical Strategy
Among the most exciting innovations in this space is microdosing psychedelics, which involves taking minimal, sub-perceptual doses of compounds like psilocybin. This approach is proving to be both safe and effective for various psychiatric conditions and cognitive enhancement strategies.
Clinicians supporting the FDA approval process for psychedelic therapy emphasize that the practice must be backed by consistent data and supervised delivery. As research advances, so too does our understanding of microdosing LSD vs psilocybin for anxiety relief, a growing area of comparison among therapists and researchers.
The key lies in presenting this model not as an endorsement of drug use, but as a framework for harm-reduction and regulated medical access—especially when discussing the differences between Psilocybe and Panaeolus mushrooms, which vary significantly in potency and legality.
Psychedelic Mushroom Biodiversity: A Global Inventory
There are currently over 180 identified psychedelic mushroom species around the world, encompassing a diverse range of genera such as Psilocybe, Panaeolus, Gymnopilus, Inocybe, and Pluteus. These mushrooms vary not only in potency but also in their geographical distribution and ecological niche.
Understanding this variety helps deepen our knowledge of which species may be best suited for use in psilocybin therapy or microdosing psychedelics protocols. For instance, Psilocybe cubensis, also known as “Golden Teacher” is widely used in clinical research, while species like Panaeolus cyanescens are gaining attention due to their high psilocybin content.
Researchers and advocates alike are working to catalog and differentiate these species more effectively, contributing to the growing body of knowledge surrounding psychedelic mushroom species and their medical potential.
Here is a more comprehensive list of Magic Mushroom Species, though not exhaustive:
Genus: Psilocybe
Psilocybe acutissima: Common Names: None specific. Regions: Japan.
Psilocybe acutipilea: Common Names: None specific. Regions: Central America.
Psilocybe aerugineomaculans: Common Names: None specific. Regions: Bolivia.
Psilocybe aucklandiae: Another species from New Zealand, it is typically found in wood chips.
Psilocybe angulospora: Common Names: None specific. Regions: Papua New Guinea.
Psilocybe angustispora: Common Names: None specific. Regions: Australia.
Psilocybe argentipes: Found in Japan, typically growing in grassy areas.
Psilocybe armandii: Common Names: None specific. Regions: Mexico.
Psilocybe atlantis: Known for producing truffles, it is found in the southeastern United States.
Psilocybe aucklandii: Common Names: None specific. Regions: New Zealand.
Psilocybe australiensis: Common Names: None specific. Regions: Australia.
Psilocybe aztecorum: Common Names: None specific. Regions: Mexico.
Psilocybe azurescens: Known for its high psilocybin content, it is native to the coastal regions of the United States.
Psilocybe baeocystis: Found in the Pacific Northwest, often called the “blue bell.”
Psilocybe banderillensis: Common Names: None specific. Regions: Mexico.
Psilocybe barrerae: Common Names: None specific. Regions: Mexico.
Psilocybe basii: Common Names: None specific. Regions: Mexico.
Also Known as Fruits of the Gods
Psilocybe bohemica: Found in Europe, particularly in the Czech Republic.
Psilocybe bonetii: Common Names: None specific. Regions: Mexico, Central America.
Psilocybe brasiliensis: Common Names: None specific. Regions: Brazil.
Psilocybe brunneocystidiata: Common Names: None specific. Regions: Colombia.
Psilocybe caeruleoannulata: Known as the “landslide mushroom,” it grows in disturbed soils in tropical and subtropical regions.
Psilocybe caerulipes: Known as the “blue-foot mushroom,” it is found in eastern North America.
Psilocybe collybioides: Common Names: None specific. Regions: Mexico, Central America.
Psilocybe columbiana: Common Names: None specific. Regions: Colombia.
Psilocybe crobula: Common Names: None specific. Regions: Europe.
Psilocybe cubensis: Commonly known as the “golden teacher,” it is one of the most well-known and widely distributed species.
Psilocybe cyanescens: Often called the “wavy cap,” it is found in wood chips and garden beds in the Pacific Northwest.
Psilocybe cyanofibrillosa: A lesser-known species found in the coastal regions of the United States.
Psilocybe fagicola: Native to Mexico, growing in deciduous forests.
Psilocybe galindoi: Also known for its truffles, it is native to Mexico.
Psilocybe heimii: Common Names: None specific. Regions: Africa (particularly found in East Africa).
Psilocybe hispanica: Recently discovered in Spain, it is one of the few European species.
Psilocybe hoogshagenii: Found in Mexico and known for its traditional use by indigenous communities.
Psilocybe liniformans: Found in Europe, particularly in the Netherlands.
More Psilocybe Species
Psilocybe mairei: Common Names: None specific. Regions: Europe (primarily found in France and surrounding areas).
Psilocybe makarorae: Found in New Zealand, growing in forests and shrublands.
Psilocybe mammillata: Common Names: None specific. Regions: Mexico.
Psilocybe mexicana: Historically used by indigenous peoples of Mexico in religious ceremonies.
Psilocybe muliercula: Common Names: None specific. Regions: Mexico.
Psilocybe neoxalapensis: Common Names: None specific. Regions: Mexico.
Psilocybe plutonia: Common Names: None specific. Regions: Mexico.
Psilocybe portoricensis: Common Names: None specific. Regions: Puerto Rico.
Psilocybe pseudoaztecorum: Common Names: None specific. Regions: Mexico.
Psilocybe pseudobullacea: Common Names: None specific. Regions: Mexico.
Psilocybe quebecensis: Discovered in Canada, it grows on moss-covered forest floors.
Psilocybe samuiensis: Discovered in Thailand, it thrives in rice paddies.
Psilocybe semilanceata: Also known as the “liberty cap,” it is prevalent in temperate regions and known for its potent effects.
Psilocybe septentrionalis: Common Names: None specific. Regions: Northern regions of the United States and Canada.
Psilocybe silvatica: Common Names: None specific. Regions: Europe, including parts of the United Kingdom and mainland Europe.
Psilocybe strictipes: Common Names: None specific. Regions: Central and South America, including Mexico and possibly parts of the Amazon rainforest.
Psilocybe stuntzii: Also known as “blue legs,” it is commonly found in the Pacific Northwest.
So many Magic Mushroom Spores to Study
Psilocybe subaeruginosa: Native to Australia and New Zealand, known for its potent effects.
Psilocybe subcaerulipes: Common Names: None specific. Regions: Eastern United States, including areas in the Appalachian Mountains.
Psilocybe subtropicalis: Common Names: None specific. Regions: Tropical and subtropical regions of Central America and possibly parts of South America.
Psilocybe tampanensis: Sometimes referred to as the “philosopher’s stone” for its truffle-like sclerotia.
Psilocybe turficola: Common Names: None specific. Regions: Mexico (often found in areas with peat bogs or turfy environments).
Psilocybe uxpanapensis: Common Names: None specific. Regions: Mexico (specifically known from the Uxpanapa region in Veracruz).
Psilocybe villarrealiae: Native to Mexico, it grows on decaying wood in cloud forests.
Psilocybe wassonii: Common Names: None specific. Regions: Mexico (specifically known from the Oaxaca region).
Psilocybe wayanadensis: Common Names: None specific. Regions: India (particularly in the Wayanad district of Kerala).
Psilocybe weldenii: Common Names: None specific. Regions: Mexico.
Psilocybe weilii: Endemic to Georgia, USA, often found in red clay soils.
Psilocybe yungensis: Found in Bolivia, growing in cloud forests.
Psilocybe zapotecorum: Named after the Zapotec people of Mexico, where it is traditionally used.
How many Species in the Genus: Panaeolus
Panaeolus africanus: Common Names: None specific. Regions: Africa (primarily found in various countries across the continent).
Panaeolus antillarum: Common Names: None specific. Regions: Caribbean (including the Antilles and nearby tropical areas).
Panaeolus bispora: Common Names: None specific. Regions: Tropical regions, including parts of Central and South America.
Panaeolus cambodginiensis: Common Names: None specific. Regions: Southeast Asia, including Cambodia and Thailand.
Panaeolus chlorocystis: Common Names: None specific. Regions: Tropical regions, including parts of Central and South America, and the Caribbean.
Panaeolus cinctulus: Common Names: None specific (often referred to by its scientific name). Regions: Widespread in temperate regions, including parts of North America, Europe, and tropical regions.
Panaeolus cyanescens: Common Names: Copelandia cyanescens, Hawaiian. Regions: Tropical and subtropical regions worldwide, including Hawaii, Southeast Asia, Central and South America, parts of Africa.
Panaeolus fimicola: Common Names: None specific. Regions: Widely distributed in tropical and subtropical regions, including parts of Central and South America.
Panaeolus microsporus: Common Names: None specific. Regions: Tropical regions, including parts of Central America and the Caribbean.
Panaeolus olivaceus: Common Names: None specific. Regions: Tropical and subtropical regions, including parts of Central and South America.
Panaeolus papilionaceus: Common Names: None specific. Regions: Tropical regions, including parts of the Caribbean and Central America.
Panaeolus rubricaulis: Common Names: None specific. Regions: Tropical and subtropical regions, including parts of Central America and South America.
Panaeolus sphinctrinus: Common Names: None specific. Regions: Tropical and subtropical regions, including parts of Central and South America.
Panaeolus tropicalis: Common Names: None specific. Regions: Tropical regions, including parts of Central and South America.
The equally large Genus: Gymnopilus
Gymnopilus aeruginosus: Common Names: None specific. Regions: Known from tropical regions, particularly in parts of Central and South America.
Gymnopilus allantopus: Common Names: None specific. Regions: Found in tropical and subtropical regions, including parts of Central and South America.
Gymnopilus braendlei: Common Names: None specific. Regions: Found in Brazil.
Gymnopilus brasiliensis: Common Names: None specific. Regions: Native to Brazil.
Gymnopilus cyanopalmicola: Common Names: None specific. Regions: Found in tropical regions, particularly in Central and South America.
Gymnopilus junonius: Common Names: Laughing Gym. Regions: Worldwide, particularly in temperate regions including North America, Europe, Asia, Australia.
Gymnopilus luteofolius: Common Names: None specific. Regions: North America, including the USA and Mexico.
Gymnopilus luteus: Common Names: None specific. Regions: Found in tropical and subtropical regions, including parts of Central and South America.
Gymnopilus purpuratus: Common Names: None specific. Regions: Found in tropical and subtropical regions, including parts of Central and South America.
Gymnopilus sapineus: Common Names: None specific. Regions: Found in the Pacific Northwest of the United States.
Gymnopilus spectabilis: Common Names: None specific. Regions: Found in North America, particularly in the Pacific Northwest and some parts of the eastern United States.
Gymnopilus subspectabilis: Common Names: None specific. Regions: Found in North America, closely related to Gymnopilus spectabilis and often found in similar regions.
Gymnopilus validipes: Common Names: None specific. Regions: Found in North America, including parts of the eastern United States and possibly the Midwest.
Gymnopilus viridans: Common Names: None specific. Regions: Found in tropical regions, including parts of Central and South America.
Gymnopilus subearlei: Common Names: None specific. Regions: Found in the southeastern United States.
Gymnopilus underwoodii: Common Names: None specific. Regions: Found in the southeastern United States.
Taxonomic group: Inocybe
Inocybe aeruginascens: Common Names: None specific. Regions: Europe, including Germany and the Czech Republic.
Inocybe coelestium: Common Names: None specific. Regions: Europe (including various countries in mainland Europe and the UK).
Inocybe corydalina: Common Names: None specific. Regions: Europe (primarily found in temperate regions of mainland Europe).
Inocybe haemacta: Common Names: None specific. Regions: North America (primarily found in the United States).
Inocybe tricolor: Common Names: None specific. Regions: North America (found in various regions, including parts of the United States).
Classification rank: Pluteus
Pluteus brunneidiscus: Common Names: None specific. Regions: Found in tropical regions, particularly in parts of Central and South America.
Pluteus cyanopus: Common Names: None specific. Regions: Found in tropical regions, including parts of Central and South America.
Pluteus glaucus: Common Names: None specific. Regions: Found in temperate regions of North America, including the United States and Canada, and parts of Europe.
Pluteus nigroviridis: Common Names: None specific. Regions: Found in tropical and subtropical regions, including parts of Central and South America.
Pluteus salicinus: Common Names: None specific. Regions: Europe, North America.
Genus: Galerina
Galerina steglichii: Common Names: None specific: Regions: Germany
Genus: Hypholoma
Hypholoma cyanescens: Common Names: None specific: Regions: Temperate regions, including Europe#
Genus: Mycena
Mycena cyanorrhiza: Common Names: None specific: Regions: Europe, North America
Genus: Pholiotina
Pholiotina cyanopus: Common Names: None specific: Regions: Europe, North America
Conclusion: A Complex Yet Promising Future
Magic mushrooms and their psychoactive compounds hold immense potential to revolutionize mental health treatment. The scientific momentum behind psilocybin therapy is undeniable, with new findings expanding our understanding of how these compounds interact with the brain and enhance healing.
Still, entrenched stigma, regulatory inertia, and financial resistance from traditional pharmaceutical interests pose serious challenges to progress. Overcoming these barriers requires not only evidence but also public pressure and political courage to reassess the outdated legal status of psychedelics.
As awareness spreads and access increases, psychedelic mushroom species may become central to the next generation of mental healthcare. With proper safeguards in place, humanity may finally unlock the full spectrum of healing that these ancient organisms offer.
More Reading
If you would like to read about the World’s Largest Mobile Microdosing Study Try this link Microdose.me
Or try Psychedelics Nonprofits & Plant Medicine Organizations Such as Psychedelics.com for loads more information
Most searched Mushroom Strains UK 2024